Anika Therapeutics | ANIK - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
Abbott USD 52.06B 69M 2026-03
Agenus USD -221.22M 49.89M 2026-03
Agios Pharmaceuticals USD 1.11B 84M 2026-03
Anika Therapeutics USD 133.9M 9.56M 2026-03
Arrowhead Research USD 613.98M 45.56M 2026-03
Enanta Pharmaceuticals USD 126.59M 61.87M 2025-12
Halozyme Therapeutics USD 219.64M 170.82M 2026-03
Heron Therapeutics USD 9.14M 4.15M 2026-03
Insmed USD 704.85M 34.12M 2026-03
Integra LifeSciences USD 1.04B 1.06M 2026-03
Intrexon USD 43.17M 75.33M 2024-06
J&J USD 81.19B 358M 2026-03
Karyopharm Therapeutics USD -292.93M 23.67M 2025-12
Ligand Pharmaceuticals USD 997.32M 19.89M 2026-03
MacroGenics USD 21.2M 34.39M 2026-03
Merit Medical Systems USD 1.63B 42.42M 2026-03
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Sanofi EUR 72.81B 1.1B 2026-03
Smith & Nephew USD 5.54B 331M 2025-12
Stryker USD 22.42B 635M 2025-12
Veracyte USD 1.34B 34.83M 2026-03
Xencor USD 515.63M 119.95M 2026-03
Zimmer Biomet Holdings USD 12.68B 16.1M 2026-03